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Abstract 
We performed a PRISMA systematic review of incretin-based therapies and effects on 
neurocognitive function in humans. There was observational evidence to support dipeptidyl 
peptidase-IV inhibitors in improving cognition, whilst glucagon-like peptide-1 had positive 
effects on cerebral glucose metabolism. Powered clinical trials are now needed in patients 
with- and without diabetes. 
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1. Introduction 
 
Dementia is expected to increase in worldwide prevalence from around 35.6 million in 2010 
to approximately 65.7 million by 2030 [1]. However, current treatments for dementia are not 
disease-modifying and produce only modest effects on cognitive decline [2]. As such, novel 
treatment strategies are needed. 
 
Incretin-based therapies, including dipeptidyl peptidase-IV (DPP-IV) inhibitors and 
glucagon-like peptide-1 (GLP-1) receptor agonists, act primarily to stimulate insulin 
secretion via the incretin effect [3]. More recently, however, incretin-based therapies been 
found to improve Alzheimer-like pathology in animal models [4,5]. However, human studies 
of incretin-based therapies on cognition have been far fewer. As more clinical trials are 
proposed, an appraisal of the current evidence base for incretin-based therapies on human 
cognition is warranted. 
 
We have therefore conducted a PRISMA systematic review examining the effects of incretin-
based therapies on neurocognitive outcomes in human studies. We hypothesised that both 
GLP-1 receptor agonists and DPP-IV inhibitors would be associated with improvements in 
cognitive function. 
 
 
2. Methods 
2.1. Design and literature search 
Following PRISMA guidelines, we systematically searched Web of Science, MEDLINE and 
PubMed for papers dating from 1st January 1900 to 23rd November 2016 using the following 
search strategy (OR’s omitted here): 
 
(cognit*; dement*;  alzheimer*;  memory;  brain;  cerebral;  positron emission;  hippocamp*;  
csf;  cerebrospinal;  cerebro-spinal) AND (lixisenatide;  glucagon-like peptide-1;  glp-1;  
albiglutide;  dulaglutide;  alogliptin;  linagliptin;  dpp-iv;  dipeptidyl;  incretin;  exenatide;  
sitagliptin;  incretin-based;  liraglutide;  exendin;  saxagliptin;  vildagliptin) NOT (rat;  
mouse;  mice). 
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2.2. Inclusion criteria 
Studies were included if they used all of the following: 1) a licensed incretin-based therapy in 
human subjects; 2) pre-and post-treatment testing using i) a validated cognitive test; ii) 
cerebrospinal fluid amyloid/tau levels; iii) cerebral amyloid burden or glucose metabolism 
using positron emission tomography (PET); or iv) change in hippocampal atrophy using 
MRI; 3) a clinical trial or longitudinal observational study design; and 4) a minimum of 10 
patients. Exclusion criteria were: 1) reanalysis of published data, 2) review article without 
original data;3) study not published in English; and 4) isolated case reports. Reference lists of 
included papers were also searched.  
 
2.3. Data extraction 
The following were extracted for each paper: year, design, baseline diabetes status, baseline 
cognitive status, sample size, age, gender, treatment and duration, cognitive testing and 
central biomarkers of cognition. 
 
 
2.4. Meta-analysis 
For studies reporting clinical outcomes against controls, we planned to perform meta-
analysis. However, as only three studies reported such data [6-8], all with varying study 
populations, meta-analysis was not performed.  
 
3. Results 
 
3.1. Overview 
From 1787 titles examined after duplicates removed, 141 abstracts were read, 13 full-text 
papers studied and 7 studies met inclusion criteria (Figure 1). Five studies were interventional 
and two observational. There was significant heterogeneity in baseline cognitive status and in 
comorbidities. Both DPP-IV inhibitor studies and one GLP-1 receptor agonist study 
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specifically targeted patients with T2D, whilst the remaining four GLP-1 receptor agonists 
studies excluded diabetes patients. Study characteristics are summarized in Table 1. 
 
 
3.2. DPP-IV inhibitors 
In an observational study of 240 people with T2D, DPP-IV inhibition was associated with 2-
year improvement in a range of cognitive parameters compared to sulphonylurea, despite no 
difference in HbA1c change [8]. In a pilot study (n=11), addition of vildagliptin to metformin 
produced no change in cognitive performance after an average of 11 months. However, this 
study was severely limited by its brief cognitive assessment and small sample size [9]. 
 
 
3.3. GLP-1 receptor agonists 
 
3.3.1. Liraglutide 
In a 6-month double-blinded trial, liraglutide produced increased cerebral metabolism of 
glucose versus placebo in multiple regions of interest [7], although the study was not 
powered to detect clinical outcomes. In an open-label study in 19 patients with comorbid 
affective disorder, 4 weeks of liraglutide was associated with improvements in multiple 
cognitive domains, although the study was uncontrolled [10]. In a cross-over trial of 
liraglutide versus placebo, 17 days of liraglutide was not associated with improvements on 
any measure of cognition compared to placebo [11].  
 
3.3.2. Exenatide 
In a 2-year open-label randomised trial, exenatide produced greater improvement in cognitive 
function compared to usual care [6]. However, the study was limited its open-label design 
and potential confounding effects of comorbid Parkinson’s disease. In a single-dose cross-
over trial, exenatide was found to increase cerebral glucose metabolism in various regions 
compared to placebo [12]. No cognitive testing was performed.  
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4. Discussion 
 
We systematically reviewed the effects of incretin-based therapies on neurocognitive function 
in humans. Despite a wide-ranging literature search, only seven studies were includable. We 
found promising observational evidence for DPP-IV inhibitors, whilst GLP-1 receptor 
agonists had positive effects on cerebral glucose metabolism in areas relevant to cognitive 
processing. No clinical trial of GLP-1 receptor agonists was powered to detect clinical effects 
and patients with diabetes were largely excluded. Trials of DPP-IV inhibitors were lacking.  
 
Implications 
Our review highlights the need for powered clinical trials of both GLP-1 receptor agonists 
and DPP-IV inhibitors for cognitive function in humans. Whilst several cognition trials are 
ongoing for GLP-1 receptor agonists, all exclude people with diabetes [13]. This may be a 
missed opportunity. Injectable GLP-1 therapies are likely to be safer and more acceptable in 
patients with T2D, whilst GLP-1 receptor agonists have positive effects on candidate 
pathways linking T2D with dementia, including hyperglycaemia, inflammation and 
depression [14,15].  
 
4.1. Limitations 
This review is limited by a lack of includable papers and lack of high-quality trial evidence. 
There was also significant between-study heterogeneity in terms of population, intervention 
and outcomes. In several studies, inclusion of patients with normal cognitive function may 
have limited effects.  
 
4.2. Conclusion 
There is currently inadequate evidence that incretin-based therapies prevent cognitive 
decline. However, observational findings for DPP-IV inhibitors are promising and GLP-1 
receptor agonists produce consistently positive effects on cerebral glucose metabolism. 
Powered clinical trials are needed in patients at risk of cognitive decline, including those 
with- and without diabetes. 
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